MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving Average - Here's Why

Key Points

• Technical move: MediciNova's shares crossed above their 200‑day moving average ($1.44), trading as high as $1.4444 and last at $1.43 on volume of 21,106 shares.
• Analyst sentiment: The consensus rating is a "Moderate Buy" with an average price target of $7.50, bolstered by several buy/strong‑buy ratings (e.g., HC Wainwright $10, Maxim Group $6).
• Company fundamentals: MediciNova is a clinical‑stage biopharma with a market cap of about $70.4M, negative EPS (recent quarter -$0.05, beating -$0.10 estimate), and its lead asset is MN‑166 (ibudilast).

MediciNova, Inc. (NASDAQ:MNOV - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.44 and traded as high as $1.4444. MediciNova shares last traded at $1.43, with a volume of 21,106 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on MNOV shares. Maxim Group reissued a "buy" rating and set a $6.00 price target on shares of MediciNova in a research note on Monday, March 23rd. HC Wainwright initiated coverage on shares of MediciNova in a report on Monday, March 16th. They set a "buy" rating and a $10.00 target price for the company. Zacks Research upgraded shares of MediciNova to a "hold" rating in a research report on Tuesday, March 17th. D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of MediciNova in a research note on Friday, January 30th. Finally, Lucid Cap Mkts upgraded MediciNova to a "strong-buy" rating in a research report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, MediciNova presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

MediciNova Trading Up 1.4%

The company has a market capitalization of $70.39 million, a P/E ratio of -5.96 and a beta of 0.61. The business has a 50 day moving average price of $1.46 and a 200 day moving average price of $1.44.

MediciNova (NASDAQ:MNOV - Get Free Report) last issued its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. The firm had revenue of $0.15 million for the quarter. On average, analysts forecast that MediciNova, Inc. will post -0.24 EPS for the current fiscal year.

Institutional Trading of MediciNova

A number of large investors have recently made changes to their positions in MNOV. State Street Corp lifted its holdings in MediciNova by 10.9% during the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company's stock worth $254,000 after acquiring an additional 19,100 shares in the last quarter. StoneX Group Inc. bought a new stake in shares of MediciNova in the fourth quarter worth about $25,000. Goldman Sachs Group Inc. bought a new stake in shares of MediciNova in the fourth quarter worth about $35,000. Citadel Advisors LLC acquired a new stake in shares of MediciNova during the third quarter worth about $92,000. Finally, Jane Street Group LLC acquired a new stake in shares of MediciNova during the fourth quarter worth about $214,000. Institutional investors own 9.90% of the company's stock.

About MediciNova

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company's leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.